66 results about "Dl-Epinephrine" patented technology

Drug products adapted for nasal delivery comprising formulations with epinephrine and devices comprising such formulations are provided. Methods of treating anaphylaxis with epinephrine products are also provided.

Provided herein are dry powder formulations comprising epinephrine alone or in combination with at least one enabling agent suitable for nasal application. Also provided are unit dose forms and devices comprising such formulations and methods of using such formulations for the treatment of various conditions including anaphylaxis, anaphylactoid reaction, respiratory conditions, hemodynamic collapse, and for administration during cardiopulmonary arrest and other life-threatening conditions.

The invention provides an epinephrine automatic injection patch and method for cardiovascular first aid, and the injection patch comprises a flexible biosensing layer which obtains the subcutaneous impedance value and vital sign parameters of a patient; the microneedle array is used for adjusting the penetration depth based on the subcutaneous impedance value and controlling the deformation quantity through a piezoelectric actuator; the micro-fluidic pulse drug delivery module is connected with the micro-needle array and is used for executing pulse type drug injection according to the penetration depth; and the control module is used for judging an autonomous circulation recovery state based on the vital sign parameters and triggering the microfluidic pulse administration module to stop injection. According to the application, by constructing a first-aid closed loop of'multi-mode physical sign dynamic monitoring-self-adaptive microneedle administration-ROSC intelligent termination ', the response speed of epinephrine injection is increased, the bioavailability is improved, the risk of excessive medication is reduced, and the gold rescue efficiency and the neurological function prognosis rate of pre-hospital cardiac arrest patients are remarkably improved.

The disclosure herein relates to the innovative epinephrine formulations in aqueous solution of medicinal products that enhance the physicochemical stabilities of epinephrine and extend the product shelf life. In some instances, the formulations comprise epinephrine or a salt thereof, a complexing agent, and a “non-sulfite” antioxidant. The epinephrine formulations substantially demonstrated the superior physicochemical stabilities to conventional sulfite formulation of commercial medications currently available. In some instances, sulfite-free formulations further provide further benefit (e.g., safety benefits) to sulfite-sensitive patients. The compositions, methods for preparing the formulations, and methods of using the same (e.g., in the treatment of anaphylaxis) are also provided.

Pharmaceutical compositions having enhanced active component permeation properties are described.

The present invention discloses an injectable composition of epinephrine, their processes, and methods of treating hypotension.

Provided herein are dry powder formulations comprising epinephrine alone or in combination with at least one enabling agent suitable for nasal application. Also provided are unit dose forms and devices comprising such formulations and methods of using such formulations for the treatment of various conditions including anaphylaxis, anaphylactoid reaction, respiratory conditions, hemodynamic collapse, and for administration during cardiopulmonary arrest and other life-threatening conditions.

The present invention discloses a method for simultaneously detecting dopamine and epinephrine, which comprises the following steps: 1) drawing a positive reduction peak current-dopamine concentration standard curve and a negative reduction peak current-dopamine and epinephrine total concentration standard curve; 2) after mixing the sample solution to be tested with a buffer solution, voltammetry detection is performed, the positive reduction peak current and the negative reduction peak current are tested, and then the concentration of dopamine is obtained by referring to the positive reduction peak current-dopamine concentration standard curve and the total concentration of dopamine and epinephrine is obtained by referring to the negative reduction peak current-dopamine and epinephrine total concentration standard curve, and then the concentration of dopamine is deducted from the total concentration of dopamine and epinephrine to obtain the concentration of epinephrine. The method of the present invention can realize the simultaneous determination of dopamine and epinephrine concentrations in biological samples, has the advantages of being simple and efficient, highly sensitive, and having strong anti-interference ability, and is suitable for on-site real-time detection.

The invention discloses a method for preparing phenylephrine hydrochloride genotoxic impurities, which comprises the following steps: by taking 3-hydroxyacetophenone as a starting material and copper bromide as a bromine source in isopropanol, reacting, and then preparing and separating to obtain dibromide impurities. The reaction condition for preparing the phenylephrine hydrochloride genotoxic impurity is mild, the operation is simple, the product purity is high, and the quality requirement for controlling phenylephrine hydrochloride can be met.

Provided herein are dry powder formulations comprising epinephrine alone or in combination with at least one enabling agent suitable for nasal application. Also provided are unit dose forms and devices comprising such formulations and methods of using such formulations for the treatment of various conditions including anaphylaxis, anaphylactoid reaction, respiratory conditions, hemodynamic collapse, and for administration during cardiopulmonary arrest and other life-threatening conditions.

The utility model discloses a device for synthesizing phenylephrine hydrochloride and recovering a catalyst, which comprises a reaction kettle, a first plate-and-frame filter, a cleaning tank, a second plate-and-frame filter, a drying tank and a catalyst recovery tank which are communicated with one another, and a feed liquid outlet of the first plate-and-frame filter is communicated with a feed liquid temporary storage tank; a stirring device is arranged in the reaction kettle, the stirring device comprises a stirring shaft arranged in the reaction kettle and a stirring motor for driving the stirring shaft to rotate, stirring blades are arranged on the stirring shaft, an auxiliary stirring mechanism is arranged at the bottom of the stirring shaft, and the auxiliary stirring mechanism comprises a conical stirring cover arranged on the stirring shaft. A plurality of spiral turbulent flow fins are arranged on the outer side of the conical stirring cover in the circumferential direction; a steam coil pipe is arranged in the drying tank, and an air inlet of the steam coil pipe is communicated with a steam storage tank. According to the device, the catalyst in the reaction can be effectively recovered, waste liquid in the process is recycled, the energy consumption is low, the heat exchange effect is good, and the recovery efficiency of the catalyst is improved.

The utility model discloses epinephrine hydrochloride liquid medicine production equipment, and relates to the technical field of liquid medicine filling. Comprising a first nitrogen gas curtain arranged at a post-filling station, a preheating station and a wire drawing and sealing station respectively, the first nitrogen gas curtain is communicated with a nitrogen gas source, and the nitrogen gas source is communicated with a second nitrogen gas curtain and a feeding barrel; the second nitrogen gas curtain is arranged at the weighing station, and the feeding barrel is arranged at the liquid medicine filling station; the first nitrogen gas curtain is used for reducing residual oxygen in the ampoule bottle from operation after filling to operation before wire drawing and sealing; the second nitrogen gas curtain is used for reducing residual oxygen in the weighing barrel; and the feeding barrel is used for batching under the protection of nitrogen. According to the utility model, the second nitrogen gas curtain is used for reducing residual oxygen in the weighing barrel, and the feeding barrel is used for batching under the protection of nitrogen, so that the residual oxygen of raw materials is effectively reduced; and meanwhile, through the first nitrogen gas curtain, the time for exposing the ampoule bottle in the air is greatly shortened, and residual oxygen in the ampoule bottle which runs from the time after filling to the time before wire drawing and sealing is effectively reduced.

Pharmaceutical compositions including topical compositions of prodrugs are described, including prodrugs of epinephrine, which can be used to treat conditions relating to allergy, dermatology and immunology and the compositions having enhanced active component permeation properties are described.

The invention provides a novel method for preparing epinephrine, which comprises the following steps of: condensing catechol serving as an initial raw material with 2-(benzyl-methyl-amino) acetic acid to obtain 2-(benzyl methyl amino)-3 ', 4'-dihydroxyacetophenone hydrochloride, performing hydrogenation reduction to obtain racemic epinephrine, performing salification resolution with L-tartaric acid, and finally regulating the pH value to 8-9 by using ammonia water to obtain the epinephrine. According to the method, 2-(benzyl-methyl-amino) acetic acid is selected as a starting material instead of chloroacetic acid in a traditional process, and two steps of chloroacetylation and methylamine in the traditional process are combined into one step, so that the environmental problem caused by the use of chloroacetic acid and monomethylamine is avoided, the reaction steps are reduced, and the yield is increased; in addition, benzyl serving as a protecting group can be synchronously removed along with reduction of carbonyl in the catalytic reduction process, so that the risk caused by multi-step hydrogenation is avoided; and finally, the racemized isomer is obtained by recycling the resolution mother liquor and then salified with L-tartaric acid for resolution and recovery of the product, so that the yield is increased, the cost is reduced, and the method has excellent industrial production and application prospects.

A pharmaceutical aerosol formulation containing pre-micronized epinephrine, a co-solvent ethanol, a surfactant polysorbate 80, and a propellant trans-1, 3, 3, 3-tetrafluoropropene (HFO-1234ze (E)) for use in a pressurized metered dose inhaler is described. The formulations provide efficient delivery of pre-micronized epinephrine particles into the respiratory tract of a patient, and have the advantages of high therapeutic efficacy, improved safety, and low global warming potential (GWP) affecting the environment.

Self-administered pharmaceutical compositions of epinephrine and its prodrugs are described as having pharmacokinetic parameters that are comparable to those compositions administered by a health care professional and by intramuscular injection.

The invention discloses a preparation method of an epinephrine substance-loaded silk fibroin microneedle transdermal patch, which comprises the following steps: dissolving aminophenylboronic acid in a dimethyl sulfoxide aqueous solution to obtain an aminophenylboronic acid solution; adding the aminophenylboronic acid solution into a silk fibroin aqueous solution, then adding 1-ethyl-(3-dimethylaminopropyl) carbodiimide hydrochloride and N-hydroxysuccinimide, and uniformly mixing to obtain a reaction solution; after the reaction of the reaction solution is finished, dialyzing to remove the small molecule catalyst and dimethyl sulfoxide to obtain a first mixed solution; the method comprises the following steps: dissolving an epinephrine substance in deionized water to obtain an epinephrine substance solution; adding the epinephrine substance solution into the first mixed solution, and uniformly mixing to obtain a second mixed solution; and casting the second mixed solution into a microneedle mold, defoaming, and drying to obtain the adrenaline substance-loaded silk fibroin microneedle transdermal patch.

The invention provides carbon-14-labeled epinephrine and a preparation method thereof, carbon-14-labeled noradrenaline and a preparation method thereof, and belongs to the field of radioactive chemistry. The invention provides a carbon-14 labeled epinephrine or a carbon-14 labeled noradrenaline, wherein the carbon-14 label is located at the a position of the benzene ring of the epinephrine or the noradrenaline. According to the present invention, the epinephrine and the noradrenaline are subjected to carbon-14 labeling, such that the metabolite ratio can be quantitatively analyzed, the dynamic conversion rule of the metabolite in the human body can be revealed, the drug administration scheme can be easily optimized, the toxicological mechanism can be easily clarified, the theoretical basis can be provided for the clinical safety application, and the scientific development of the first-aid drug can be promoted.

The present disclosure is directed to a pharmaceutical premix phenylephrine formulation comprising phenylephrine hydrochloride and a salt, e.g., sodium chloride, where the formulation has a pH from about 3.0 to 6.5. Also presented is a system containing an oxygen scavenger, a photosensitive overpouch, and a pharmaceutical premix phenylephrine formulation. Methods of treating hypotension, e.g., resulting primarily from vasodilation, in such settings as septic shock or anaesthesia, in a human subject are also described.

Drug products adapted for nasal delivery comprising formulations with epinephrine and devices comprising such formulations are provided. Methods of treating anaphylaxis with epinephrine products are also provided.

Pharmaceutical compositions of epinephrine and prodrugs thereof are described, as well as compositions having enhanced permeability of active ingredients for administration at specific residence times.

The present invention provides a method for determining the amount of one or more of one or more noradrenaline (NE), epinephrine (E), and dopamine (D) in a sample using mass spectrometry. The methods generally involve ionizing one or more of NE (or derivatized NE), E (or derivatized E), and D (or derivatized D) in a sample, and detecting and quantifying the amount of ions to determine the amount of one or more of NE, E, and D in the sample.

The present invention relates to a contour injection composition, and more specifically, is characterized by an injection composition comprising a solvent, aminophylline, procaine, epinephrine, and hyaluronidase, the injection composition comprising, on the basis of the entire composition, 500 to 700 IU units hyaluronidase, and 0.05 to 0.15% (w / v) aminophylline, 0.01 to 0.03% (w / v) procaine, 0.001 to 0.006% (w / v) epinephrine, and the remainder the solvent, wherein the solvent is half saline and distilled water. According to the present invention, the injection composition has excellent fat decomposition and fat destruction effects and cellulite reduction effect, as well as effect in improving a circulation function, thereby reducing subcutaneous fat in a desired area, and having the advantages not only of improving body and facial lines by improving elasticity, but also not causing side effects such as redness, itchiness, swelling, skin depression, and skin sagging.

A pharmaceutical composition in the form of droplets for oral administration is disclosed. The pharmaceutical composition is an aqueous solution comprising sodium chloride in an amount of 0.6% to 3% by weight per volume, at least one active ingredient selected from naloxone, yohimbine, albuterol, epinephrine, buprenorphine, and exosomes in an amount of 0.01% to 25% by weight per volume, and having a pH from 3 to 7.5. The composition is converted into droplets with diameters of 0.5 to 5 microns using an atomizer with a vibrating mesh membrane undergoing piezoelectric vibration at a frequency of 25 to 400 kilohertz. The process involves providing the composition in a capsule, inserting the capsule into the atomizer, and activating the atomizer to produce droplets. This system provides precise, efficient, and patient-friendly oral delivery of medications.

Pharmaceutical compositions comprising epinephrine, methods of administration, and methods of making the same. Compositions may comprise at least one of an active agent, a pH raising agent, an antioxidant, a transition metal complexing agent, a pH lowering agent, a tonicity regulating agent, optionally a preservative, and optionally a solvent.

Pharmaceutical compositions comprising epinephrine, methods of administration, and methods of making the same. Compositions may comprise at least one of an active agent, a pH raising agent, an antioxidant, a transition metal complexing agent, a pH lowering agent, a tonicity regulating agent, optionally a preservative, and optionally a solvent.

Provided herein are dry powder formulations comprising epinephrine alone or in combination with at least one enabling agent suitable for nasal application. Also provided are unit dose forms and devices comprising such formulations and methods of using such formulations for the treatment of various conditions including anaphylaxis, anaphylactoid reaction, respiratory conditions, hemodynamic collapse, and for administration during cardiopulmonary arrest and other life-threatening conditions.

It relates to novel formulations of epinephrine that comprise polyoxymethylene alkyl ethers as a permeation enhancer, methods of administering the formulation, and uses thereof.

The invention discloses a refining method of epinephrine tartrate, and belongs to the technical field of organic synthesis of medicines. The method comprises the following steps: by taking a mixed solvent of acetone and water as a recrystallization system, dissolving an epinephrine tartrate crude product in deoxygenated water, slowly adding acetone to form the mixed solvent, carrying out low-temperature crystallization under the protection of nitrogen, drying an obtained wet product under a low-temperature vacuum condition, intermittently introducing nitrogen to maintain an oxygen-free environment, and carrying out recrystallization to obtain the epinephrine tartrate. The high-purity epinephrine tartrate is obtained. According to the method, through combination of whole-process nitrogen protection and low-temperature crystallization, generation of oxidation impurities is effectively inhibited, the solution color and clarity of the product are remarkably improved, and meanwhile, the content of chiral impurities of D-epinephrine is further reduced. The yield of the refined product can reach 85%, the content is greater than or equal to 99.5%, the content of key impurities meets the limit requirements of European Pharmacopoeia, and the solution is colorless and clear and is suitable for large-scale production.